QNTM

Investor Moves

Name	Value	Action	Change	Price	Current Price
Ken GriffinCitadel Advisors $-115.8K ExitQ1 2026 $116k -- $6.86

News

globenewswire.comIBN Announces Latest Episode of The BioMedWire Podcast Featuring Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd.globenewswire.comJun 2

globenewswire.comQuantum BioPharma Engages Stocks.news For Investor Relations, Marketing Services And Lead Generation Campaignsglobenewswire.comJun 2

globenewswire.comQuantum BioPharma Provides Corporate Updateglobenewswire.comJun 1

feeds.benzinga.comQuantum BioPharma Momentum Score Surges As Investors Cheer Progress In MS Researchfeeds.benzinga.comMay 28

Trade QNTM

About Quantum BioPharma Ltd.

Quantum BioPharma Ltd., a biopharmaceutical firm headquartered in Toronto, Canada, is dedicated to the discovery and advancement of biotechnological solutions and drug candidates. The company focuses on addressing complex neurodegenerative, inflammatory, and metabolic conditions, alongside alcohol use disorder, with its pipeline featuring a range of drug candidates at varying stages of development. Its operations are divided into two main divisions: its core biopharmaceutical activities and strategic investment holdings. A flagship asset is Lucid-MS, a novel, proprietary chemical entity currently in Phase 2 clinical trials. Preclinical data indicates its potential to prevent and reverse the degradation of myelin, a key process underlying multiple sclerosis. Furthermore, Quantum BioPharma is developing a therapeutic solution for alcohol addiction, intended for application in hospital and clinical environments. The company's strategic investments portfolio includes various loans collateralized by residential real estate. Previously known as FSD Pharma Inc., the company adopted its current name, Quantum BioPharma Ltd., in August 2024.

CEO: Zeeshan Saeed
IPO Date: Jun 8, 2018

Market Data

Open: $3.98
High: $4.10
Low: $3.75
Volume: 154.5K
Avg Volume: 504.3K
52W High: $32.58
52W Low: $2.07

Valuation

Market Cap: $17M
Enterprise Value: $14M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-8.4M
Revenue: $0
Net Income: $-26M
Cash: $1.9M
Debt: $1.9M

Events

EarningsAug 6

EPS est. -0.41353